Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):64-71. doi: 10.1016/j.ijrobp.2009.07.1693. Epub 2009 Dec 16.
To analyze the outcomes of gamma knife stereotactic radiosurgery (SRS) for residual or recurrent craniopharyngiomas and evaluate the factors that optimized the tumor control rates.
A total of 46 patients with craniopharyngiomas underwent 51 SRS procedures at University of Pittsburgh between 1988 and 2007. The median tumor volume was 1.0 cm(3) (range, 0.07-8.0). The median prescription dose delivered to the tumor margin was 13.0 Gy (range, 9-20). The median maximal dose was 26.0 Gy (range, 20-50). The mean follow-up time was 62.2 months (range, 12-232).
The overall survival rate after SRS was 97.1% at 5 years. The 3- and 5-year progression-free survival rates (solid tumor control) were both 91.6%. The overall local control rate (for both solid tumor and cyst control) was 91%, 81%, and 68% at 1, 3, and 5 years, respectively. No patients with normal pituitary function developed hypopopituitarism after SRS. Two patients developed homonymous hemianopsia owing to tumor progression after SRS. Among the factors examined, complete radiosurgical coverage was a significant favorable prognostic factor.
SRS is a safe and effective minimally invasive option for the management of residual or recurrent craniopharyngiomas. Complete radiosurgical coverage of the tumor was associated with better tumor control.
分析伽玛刀立体定向放射外科(SRS)治疗颅咽管瘤残留或复发的结果,并评估优化肿瘤控制率的因素。
1988 年至 2007 年期间,共有 46 例颅咽管瘤患者在匹兹堡大学接受了 51 次 SRS 治疗。肿瘤体积中位数为 1.0cm³(范围,0.07-8.0)。肿瘤边缘的中位处方剂量为 13.0Gy(范围,9-20)。最大剂量中位数为 26.0Gy(范围,20-50)。平均随访时间为 62.2 个月(范围,12-232)。
SRS 后 5 年的总生存率为 97.1%。3 年和 5 年无进展生存率(实体瘤控制)均为 91.6%。总体局部控制率(包括实体瘤和囊肿控制)分别为 1、3 和 5 年的 91%、81%和 68%。无正常垂体功能的患者在 SRS 后发生垂体功能减退。2 例患者因 SRS 后肿瘤进展出现同向偏盲。在所检查的因素中,完全放射外科覆盖是一个显著的有利预后因素。
SRS 是治疗颅咽管瘤残留或复发的一种安全有效的微创选择。肿瘤的完全放射外科覆盖与更好的肿瘤控制相关。